A RETROSPECTIVE ANALYSIS OF THE EXPERIMENTAL AND CLINICAL STUDY OF THE ANTIVIRAL HERBAL DRUG FLAKOZID IN VIRAL INFECTIONS CHARACTERIZED BY LESIONS OF THE SKIN AND MUCOUS MEMBRANES

Introdction. Herpesvirus infections are one of the leading medical and social problems and are defined as a "global problem of humanity". Currently, the most common are simple (HSV-1, HSV-2) and herpes zoster (VVO). For the prevention and treatment of herpesvirus infections, antiviral drugs are prescribed, one of which is the herbal drug Flakozid, 0.1 g tablets for oral administration. The aim of the work was a retrospective analysis of the results of an experimental and clinical study of Flakozid in simple recurrent and herpes zos-ter, chickenpox. Material and methods. The antiviral properties of Flakozid were studied in in vitro experiments, in the culture of chicken embryo fibroblast cells against three strains of herpes virus (2 strains geratogenic "10", "90" and dermatogenic strain "64") and in vivo − on a model of experimental herpetic encephalitis of white mice in doses from 20 mg/kg to 500 mg/ kg with the administration of per os and subcutis. The results of the clinical study of Flakozid were analyzed in 313 patients (adults and children) with simple recurrent herpes 202 patients, including genital – 65, with herpes zoster – 45, chickenpox – 66. The criteria for the effectiveness of antiviral therapy of herpes were the duration of inflammatory phenomena, a reduction in the number and duration of relapses; in chickenpox – the severity of symptoms of intoxication, the nature and spread of rashes, the degree of their re-verse development. Flakozid was prescribed 0.2–0.6 g per day. Results. Experimental studies have shown that Flakozid had a high viral inhibitory effect against Herpes simplex. Treatment with Flakozid led to a high therapeutic effect: complete resolution of rashes in simple recurrent herpes after an average of 6-14 days, genital – 8-15 days, shingles – 7-15 days and shortening the duration of relapses by 2 times. The therapeutic effect of Flakozid in the treatment of genital herpes was noted in 91.6% of cases and exceeded the effect of Alpizarin (40%); in chickenpox –74%. Conclusions. The high therapeutic effect of Flakozid in the treatment of viral infectious and inflammatory dermatoses in adults and children allowed it to be recommended in a wide clinical practice in the treatment of simple recurrent herpes, including genital and extragenital localization; herpes zoster, chickenpox.